Investor Home

Corporate Profile

Apricus is committed to developing novel therapies in areas of high unmet needs. We have disciplined leadership focused on execution and are driving near-term shareholder value through regulatory approval, commercialization and partnering initiatives.

Recent Newsmore >
DateTitle
10/31/18Apricus Biosciences Provides Corporate Update and Third Quarter 2018 Financial Results
Company Merger with Seelos Therapeutics, Inc. Expected to Close in Fourth Quarter 2018 Apricus Shareholders Expected to Own ~15% of Estimated $94 Million Combined Company Valuation at Closing SAN DIEGO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company historically focused on seeking to advance innovative medicines in urology and rheumatology, today reported financial results for the third quarter and year-to-date for 2018 and provided a... 
08/09/18Apricus Biosciences Provides Corporate Update and Second Quarter 2018 Financial Results
Company Enters Into Merger Agreement with Seelos Therapeutics, Inc. Apricus Shareholders Expected to Own ~14% of Combined Company Based on Estimated $90 Million Valuation at Closing Merger Expected to Close in Fourth Quarter 2018 SAN DIEGO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company historically focused on seeking to advance innovative medicines in urology and rheumatology, today reported financial results for the second quarter ... 
07/30/18Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders
Transaction to result in Nasdaq-listed company focused on developing novel products to treat central nervous system diseases Transaction expected to advance Seelos’ robust, late-stage pipeline of five programs, with near-term clinical and regulatory milestones Ownership split of merged company anticipated to be approximately 86% Seelos shareholders and 14% Apricus shareholders Terms of the transaction to include a Contingent Value Right (CVR) per share to Apricus shareholders of reco... 
Event Calendarmore >
November 2018?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SMTWTFS
-4-3-2-1123
45678910
11121314151617
18192021222324
25262728293051
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Apricus Biosciences, Inc. posts new information to the site. Just enter your e-mail address and click Submit.